HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Geisler, T. Articles by Gawaz, M. Search for Related Content PubMed PubMed Citation Articles by Geisler, T. Articles by Gawaz, M. Social Bookmarking                What's this?

Platelet Response to Clopidogrel Is Attenuated in Diabetic Patients Undergoing Coronary Stent Implantation

Department of Cardiology/Internal Medicine, University Hospital Tübingen, Tübingen, Germany

Address correspondence and reprint requests to Meinrad Gawaz, MD, Medizinische Klinik III, Universitätsklinikum Tübingen, Otfried-Müllerstr.10, 72076 Tübingen, Germany. E-mail: meinrad.gawaz@med.uni-tuebingen.de

Abbreviations: ACS, acute coronary syndrome • ARMYDA, Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty • CAD, coronary artery disease • EPISTENT, Evaluation of Platelet IIb/IIIa Inhibitor for Stenting Trial • LTA, light transmittance aggregometry • PCI, percutaneous coronary intervention • RPA, residual platelet activity

The first 20% of the full text of this article appears below.

	INTRODUCTION

 
Type 2 diabetes is accompanied by platelet function disorders leading to an accelerated process of atherosclerosis and increased risk for atherothrombotic complications (1–4). Previous data (5,6) suggest a worse outcome for diabetic patients after acute coronary events. Recently, a high variability of response to clopidogrel measured by platelet function tests has been reported (7) among patients with percutaneous coronary intervention (PCI), and hyporesponsiveness to clopidogrel has been considered to influence cardiac outcome in these patients (8–10). Impaired response to antiplatelet therapy in diabetic patients has been reported (11,12) in small patient collectives. However, little is known about the effects of type 2 diabetes on response after a 600-mg clopidogrel loading dose in large unselected cohorts of patients with symptomatic coronary artery disease (CAD).

	RESEARCH DESIGN AND METHODS—

 
Type 2 diabetic and nondiabetic patients treated by coronary stenting for symptomatic CAD were consecutively enrolled in this study. The protocol was approved by the local ethics committee, and signed informed consent was obtained from all patients. Patients with known platelet function disorders, thrombocytopenia (<10⁵ cells/mm³), or any contraindications against clopidogrel were excluded. A loading dose of 600 mg clopidogrel was given to all patients before PCI, followed by 75 mg every day. All patients received a daily dose of 100 mg aspirin before PCI. A standard dose of heparin was given to all patients immediately before PCI unless there were no contraindications. Type 2 diabetes was defined according to the recommendations of the American Diabetes Association (13).

Patient blood was collected 6 h (46.6 ± 99.3 h) after administration of 600 mg clopidogrel, when maximum platelet inhibition was expected (14. . . [Full Text of this Article]

	RESULTS—

 

	CONCLUSIONS—

 

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				S. D. Wiviott, E. Braunwald, D. J. Angiolillo, S. Meisel, A. J. Dalby, F. W.A. Verheugt, S. G. Goodman, R. Corbalan, D. A. Purdy, S. A. Murphy, et al. Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38 Circulation, October 14, 2008; 118(16): 1626 - 1636. [Abstract] [Full Text] [PDF]

				D. J. Angiolillo, P. Capranzano, S. Goto, M. Aslam, B. Desai, R. K. Charlton, Y. Suzuki, L. C. Box, S. B. Shoemaker, M. M. Zenni, et al. A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study Eur. Heart J., September 2, 2008; 29(18): 2202 - 2211. [Abstract] [Full Text] [PDF]

				T. Geisler, C. Zurn, M. Paterok, K. Gohring-Frischholz, B. Bigalke, K. Stellos, P. Seizer, B. F. Kraemer, J. Dippon, A. E. May, et al. Statins do not adversely affect post-interventional residual platelet aggregation and outcomes in patients undergoing coronary stenting treated by dual antiplatelet therapy Eur. Heart J., July 1, 2008; 29(13): 1635 - 1643. [Abstract] [Full Text] [PDF]